Gilead files first hepatitis delta therapy with FDAGilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) Share XGilead files first hepatitis delta therapy with FDAhttps://pharmaphorum.com/news/gilead-files-first-hepatitis-delta-therapy-with-fda/
Gilead moves closer to Chinese filing for Trodelvy in TNBCGilead Sciences’ Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried Share XGilead moves closer to Chinese filing for Trodelvy in TNBChttps://pharmaphorum.com/news/gilead-moves-closer-to-chinese-filing-for-trodelvy-in-tnbc/
Gilead tags Merck for first-line triple negative breast cancer trialTake two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? Share XGilead tags Merck for first-line triple negative breast cancer trialhttps://pharmaphorum.com/news/gilead-tags-merck-for-first-line-triple-negative-breast-cancer-trial/
Kite claims a first for CAR-T Tecartus in adult leukaemiaThe FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor Share XKite claims a first for CAR-T Tecartus in adult leukaemiahttps://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/
Galapagos’ long-serving CEO Onno van de Stolpe to retireAfter 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided Share XGalapagos’ long-serving CEO Onno van de Stolpe to retirehttps://pharmaphorum.com/news/galapagos-long-serving-ceo-onno-van-de-stolpe-to-retire/
Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T caseGilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Share XAppeals court reverses $1.2bn judgment against Gilead in BMS CAR-T casehttps://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/
Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancerGilead Sciences’ Kite Pharma has mapped out another route to the development of allogeneic or ‘off-the-shelf’ cell therapies Share XKite takes the ‘Appian way’ to off-the-shelf cell therapies for cancerhttps://pharmaphorum.com/news/kite-takes-the-appian-way-to-off-the-shelf-cell-therapies-for-cancer/
Arcus’ CMO Grossman jumps ship to join Gilead’s cancer pushGilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief Share XArcus’ CMO Grossman jumps ship to join Gilead’s cancer pushhttps://pharmaphorum.com/news/arcus-cmo-grossman-jumps-ship-to-join-gileads-cancer-push/
BioNTech grows in cell therapies, buying Kite’s TCR platformBioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 Share XBioNTech grows in cell therapies, buying Kite’s TCR platformhttps://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/
